“The Outcomes of Myocardial Infarction Undergoing Thrombolysis Treatment with Streptokinase and Reteplase’’

Abstract

To compare and assess the outcomes of patients with myocardial infarction   undergoing thrombolysis, specifically evaluating the efficacy and safety of two commonly  used thrombolytic agents, Streptokinase, and Reteplase.

Objectives:1. To compare the Efficacy of Streptokinase and Reteplase in achieving reperfusion.

1. To examine the Safety Profiles of Streptokinase and Reteplase .


2. To analyze Short-Term and Long-Term Clinical outcomes.


3. To explore Subgroup Analyses Based on Patient characteristics.


4. To provide Evidence-Based Recommendations for Clinical decision making.

  Methods: Prospective observational study in the clinical management techniques

    in thrombolysed case patients.

    New life heart and Multi-speciality Hospital, Latur.

 The present study was carried out from Nov 2023 to May 2024.

 Study has included the total no of 31 cases for thrombolytic treatment.

Clinical outcomes of patients thrombolysed with Streptokinase and Reteplase

The sampling of study at the allotted hospital included the collection of Case papers of patients hospitalized, thereby taking all the data from the admission of the patient till the recovery he/she acquires. The data collected includes all the diagnostic parameters such as vitals monitoring, ECG, adviced tests for the prognostic diagnosis, etc

Results: "Effects of thrombolytics” on the cardiac complications is the prospective observational study carried out in November 2023 to April 2024 at New Life Heart Care And Multi-speciality Hospital Latur. BP and HR. Study performed according to protocol given by Institutional Ethics Committee (IEC). Subjects are included according to patients selection criteria.In this study total 31 patients are included according to inclusion criteria .. clinical practice  help optimize treatment strategies.Investigated the impact of the time elapsed from symptom onset to the initiation of thrombolysis on outcomes for both streptokinase and reteplase.

Conclusions: Both Streptokinase and Reteplase are effective thrombolytic agents in restoring blood flow to the heart in cardiac patients. While both drugs carry risks of bleeding complications, allergic reactions, and reperfusion arrhythmias, Reteplase may have a slightly lower incidence of adverse effects compared to Streptokinase. Streptokinase generally tends to be more cost-effective compared to Reteplase, making it a preferred option in resource-limited settings or for patients with financial constraints.